Long-Term Effects of Trilostane in Dogs with Cushing's Syndrome
January 2011
TLDR Trilostane generally improved symptoms in dogs with Cushing's syndrome, but dosage adjustments were needed over time.
The study evaluated the long-term effects of trilostane in 33 dogs with Cushing's syndrome, focusing on treatment response, dosage impact on the adrenal cortex, and adverse effects. Trilostane was generally well-tolerated, with 24 out of 25 dogs showing improvement in PU/PD symptoms and 9 out of 11 dogs with alopecia experiencing hair regrowth. Some dogs required dosage adjustments, typically stabilizing between 4.0 and 6.0 mg/kg/day after 2 years. Adverse effects were mainly mild hypoadrenocorticism symptoms, with no significant drug interactions observed. The study suggested a need for higher doses for treatments extending beyond 1.5 years and highlighted the necessity for further research with more subjects to confirm findings.
